Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 5/20 | 0.86 |
| ▸ | PDE2A | O00408 | 1/20 | 0.86 |
| ▸ | PDE1A | P54750 | 1/20 | 0.86 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.86 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29801523 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Potassium SCHEMBL7504150 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL5917668 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Hydrochloric Acid SCHEMBL7502602 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7504141 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL5917665 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7502434 | 0.96 | PDE4A (0.92) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7500079 | 0.93 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL2232142 | 0.92 | PDE5A (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| Potassium Ion SCHEMBL7504145 | 0.92 | PDE5A (0.97) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-8217049-B2 | Use of type V phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine | ANOXA CORP. (US) | 2012-07-10 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| EP-2051759-A1 | USE OF TYPE V PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF EXERCISE INDUCED PULMONARY HEMORRHAGE IN THE EQUINE | Perry, Bryan J. (US) | 2009-04-29 | — | — | EP | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| EP-1858554-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE 5-INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-11-28 | — | — | EP | claimed |
| WO-2007130427-A1 | USE OF TYPE V PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF EXERCISE INDUCED PULMONARY HEMORRHAGE IN THE EQUINE | PERRY BRYAN J (US) | 2007-11-15 | — | — | WO | claimed |
| EP-1120120-A1 | TABLETS IMMEDIATELY DISINTEGRATING IN THE ORAL CAVITY | Eisai Co., Ltd. (JP) | 2001-08-01 | — | — | EP | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| US-5765548-A | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine | ANOXA CORP. | 1998-06-16 | — | — | US | claimed |
| WO-1997041912-A1 | USE OF NITRIC OXIDE IN THE TREATMENT OF EXERCISED INDUCED PULMONARY HEMORRHAGING IN EQUINE | PERRY BRYAN J (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | claimed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | PDE4A 118/4885PDE4B 49/4885PDE4C 111/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE4A 118/4885PDE4B 49/4885PDE4C 111/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE4A 118/4885PDE4B 49/4885PDE4C 111/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE4A 118/4885PDE4B 49/4885PDE4C 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.